Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

23.52CHF
19 Jul 2019
Change (% chg)

CHF0.40 (+1.73%)
Prev Close
CHF23.12
Open
CHF23.30
Day's High
CHF23.70
Day's Low
CHF23.22
Volume
270,994
Avg. Vol
294,831
52-wk High
CHF26.00
52-wk Low
CHF15.20

Summary

Name Age Since Current Position

Jean-Pierre Garnier

71 2017 Non-Executive Independent Chairman of the Board

Jean-Paul Clozel

64 Chief Executive Officer, Delegate of the Board, Member of the Executive Board

Andre Muller

55 Chief Financial Officer, Executive Vice President, Member of the Executive Board

Martine Clozel

63 Executive Vice President, Chief Scientific Officer, Member of the Executive Board

Simon Jose

53 2018 Executive Vice President, Chief Commercial Officer, Member of the Executive Board

Guy Braunstein

62 Executive Vice President, Head of Global Clinical Development, Member of the Executive Board

Mathieu Simon

63 2019 Non-Executive Director

Robert Bertolini

57 2017 Non-Executive Independent Director

John Greisch

63 2017 Non-Executive Independent Director

Viviane Monges

55 2018 Non-Executive Independent Director

Biographies

Name Description

Jean-Pierre Garnier

Dr. Jean-Pierre (JP) Garnier, Ph.D., is Non-Executive Independent Chairman of the Board of Idorsia Ltd. He holds Various management positions at ScheringPlough. Within SmithKline Beecham, President of the pharmaceutical business in North America (1990), elected to the Board of Directors (1992), Chairman, Pharmaceuticals (from 1994), Chief Operating Officer (COO) (from 1995) and Chief Executive Officer (CEO) (from April 2000). First CEO of GlaxoSmithKline, 2001–2008. CEO of Laboratoires Pierre Fabre, 2008–2010. He is a Member of the Board of Directors of three listed companies, United Technologies Corporation, Radius Health, Inc., Carmat SA (Chairman) and former Chairman of one unlisted company, Alzheon, Inc. (until August 2018). Operating Partner of the unlisted company Advent International Corporation. Member of the Advisory Board of Newman’s Own Foundation. Officer of the Legion of Honour and Knight Commander of the Order of the British Empire. He holds MSc in Pharmaceutical Science and PhD in Pharmacology from Louis Pasteur University, Strasbourg, France; MBA from Stanford University, California, US.

Jean-Paul Clozel

Dr. Jean-Paul Clozel serves as Chief Executive Officer, Delegate of the Board, Member of the Executive Board at Idorsia Ltd. He founded Actelion in 1997 together with his wife, Martine Clozel, Walter Fischli, Thomas Widmann and Andre J. Mueller. First mainly focusing on research and development, he became Chief Executive Officer and executive member of Actelion’s board of directors to take Actelion public in April 2000. Previously, Dr. Clozel spent several years as a practicing cardiologist. He then moved to applied research, spending 12 years at F. Hoffmann-La Roche Ltd.

Andre Muller

Mr. Andre C. Muller is Chief Financial Officer, Executive Vice President, Member of the Executive Board at Idorsia Ltd. He joined Idorsia from Actelion, where he has worked since 2013. Previously, Mr. Muller worked at Pierre Fabre SA, where he held various positions from 1994 until 2011, most recently as chief financial officer from 2002. Mr. Muller holds an MBA from EM LYON Business School in Lyon, France.

Martine Clozel

Ms. Martine Clozel is Executive Vice President, Chief Scientific Officer, Member of the Executive Board at Idorsia Ltd. She joined Idorsia from Actelion, which she co-founded in 1997. Previously, Ms. Clozel spent 11 years at F. Hoffmann-La Roche Ltd, where she initiated the research project on endothelin and endothelin receptor antagonists. Ms. Clozel is a pediatrician specializing in neonatal intensive care, has an MD degree from Nancy University, France, and received further training in physiology and pharmacology from McGill University, Montreal, Canada and the University of California, San Francisco, U.S.

Simon Jose

Mr. Simon Jose has been Executive Vice President, Chief Commercial Officer, Member of the Executive Board of Idorsia Ltd since December 1, 2018. From 1995 to 2012 he held various marketing and General Manager positions at Glaxosmithkline in the United Kingdom, United States, and Denmark. He was Global President of Stiefel, a GSK company (2012–2014): Senior Vice President, Head Global Franchises & Platforms (Pharmaceuticals) at GSK (2014–2018). He holds Bachelor of Science in Medical Biochemistry with Honors from the University of Birmingham.

Guy Braunstein

Dr. Guy Braunstein serves as Executive Vice President, Head of Global Clinical Development, Member of the Executive Board at Idorsia Ltd. He joined Idorsia from Actelion, where he has worked since 2009. Prior to his position at Actelion, Dr. Braunstein was chief medical officer at Merck Serono, having served for four years before that as chief medical officer (international) at Serono. Previously, Dr. Braunstein held various executive positions at Astra, Glaxo-Wellcome, GSK, Fisons, Rhone-Poulenc Rorer and Chiron. Dr. Braunstein is an MD, pulmonologist and holds a Ph.D. in life science from Paris University, France.

Mathieu Simon

Dr. Mathieu Simon serves as Non-Executive Director of the Company. He is a ormer Chairman of the Board of Cellartis AB; Executive Vice-President, Chief Operating Officer of Cellectis Group, CEO of Cellectis Therapeutics and CEO of ECTYCELL; Managing Director, Head of Global Pharma operations at Pierre Fabre SA: various management and EU regional management roles as well as senior corporate functions at WYETH Pharmaceuticals.

Robert Bertolini

Mr. Robert J. (Bob) Bertolini, CPA, serves as Non-Executive Independent Director at Idorsia Ltd. He is Chairman of the Finance & Audit Committee at the Company. He joined the board of Actelion in 2011. He has been Member of the Board of Bristol Myers Squibb, Charles River Laboratories International, Inc. and Physicians World, LLC (unlisted), and is a former Member of the Board of Genzyme Corporation. Mr. Bertolini formerly served as Executive Vice President and Chief Financial Officer at Schering Plough Corporation, was formerly President and Chief Financial Officer of Bausch & Lomb Inc., and spent 20 years at PricewaterhouseCoopers. Mr. Bertolini is a Certified Public Accountant.

John Greisch

Mr. John J. Greisch serves as Non-Executive Independent Director of Idorsia Ltd. He has been CFO, 2004–2006, and President, International Operations, 2006–2009, at Baxter International, Inc.; President and CEO of Hill-Rom Holdings, Inc., 2010–2018. He is a Member of the Board of one listed company, Catalent, Inc, and one unlisted company, Viant Corporation (Chairman). Member of the Board of Ann and Robert Lurie Children’s Hospital. Former member of the Board of the listed company Hill-Rom Holdings, Inc (until May 2018), and the unlisted company AdvaMed, Advanced Medical Technology Association (until May 2018). He holds Bachelor’s degree in Business Administration from Miami University, Oxford, Ohio, US; Master’s degree in Management (MBA equivalent) from Northwestern University, Illinois, US.

Viviane Monges

Ms. Viviane Monges serves as Non-Executive Independent Director of Idorsia Ltd since April 24, 2018. She is Member of the Finance & Audit Committee and Member of the Nominating, Governance & Compensation Committee at the Company. She held various executive positions such as Head of Finance and Control NBE at Nestlé, 2014–2017, Group CFO of Galderma, 2010– 2014, Global Division CFO at Novartis OTC, 2006–2010, Global Pharma Business unit CFO and EMEA CFO at Wyeth, 1997–2006. She is a Member of the Board of Directors of one listed company, UCB, and three unlisted companies, Novo Holdings, NeoMedLight and Voluntis SA.

Basic Compensation